Zydus Cadila gets USFDA’s nod for Cisatracurium Besylate Injection

05 Nov 2019 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Cisatracurium Besylate Injection USP 10 mg (base)/5 mL (2 mg/mL) and 200 mg (base)/20 mL (10 mg/mL) Single-Dose Vials (Preservative-free)(US RLD- Nimbex).

This medication is used to relax the muscles. It works by blocking the signals between one’s nerves and one’s muscles. This medicine is given before general anaesthesia in preparing for surgery. It will be manufactured at Liva Pharmaceuticals, a wholly-owned subsidiary company of Cadila Healthcare.

The group now has 275 approvals and has so far filed over 360 ANDAS since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

953.50 20.10 (2.15%)
25-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1520.55
Dr. Reddys Lab 6217.15
Cipla 1405.40
Zydus Lifesciences 953.50
Lupin 1589.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.